Momelotinib in MF: Data from the SIMPLIFY-1 Trial

The SIMPLIFY-1 trial investigated the use of momelotinib in JAK inhibitor-naive patients with myelofibrosis, primarily symptomatic with spleen enlargement, hepatomegaly, or anemia; results showed momelotinib led to improved transfusion independence, reduced transfusion burden, and decreased anemia compared to ruxolitinib.

EP: 1.Case Presentation: A 76-Year-Old Woman With Newly-Diagnosed Myelofibrosis (MF)

EP: 2.Defining Myelofibrosis

EP: 3.Types of Myelofibrosis

EP: 4.Treatment Goals for Patients With MF

EP: 5.When to Initiate Therapy in Patients With MF

EP: 6.Rationale for Treatment With Momelotinib in Patients With MF

EP: 7.Managing Anemia in Patients With MF Receiving Momelotinib

Now Viewing

EP: 8.Momelotinib in MF: Data from the SIMPLIFY-1 Trial

EP: 9.Other Therapies Approved for Patients With MF

EP: 10.Advice for Clinicians Treating Patients With MF

Recent Videos